Omega Diagnostics (LON: ODX) and Abingdon Health (LON: ABDX) shares rose on Tuesday morning after they noted the publication of an article demonstrating the use of the AbC-19 rapid antibody test to monitor antibody responses against Covid-19 variants.
Omega and Abingdon are partners in the UK Rapid Test Consortium.
The publication, from researchers at the University of Birmingham, explains that the AbC-19 test can monitor antibody response following vaccination or natural infection. An initial study was conducted using AbC-19 to test patients who received the Pfizer or AstraZeneca vaccine.
The paper shows differences in strength of antibody response with the Pfizer and AstraZeneca vaccines and the antibody responses to the original variant on which the vaccines are based.
The study was conducted using the AbC-19 test and prototypes based on different covid variants.
Shares of Omega jumped to a high of 54.3p following the news. They are currently trading at 51.35p, up 0.7%. Meanwhile, Abingdon Health's share price is up 2.65% at 42.6p.
Should you invest in Omega Diagnostics shares?
Omega Diagnostics shares are traded on the London stock exchange's AIM market (the alternative investment market), which is the submarket specifically for smaller companies. AIM stocks are attractive to investors as they have tax advantages and smaller companies have the potential to benefit from rapid growth. But are Omega shares the best buy? Our stock market analysts regularly review the market and share their picks for high growth companies